Although the exact mechanisms of action of CTLA-4 blockade remain unclear, the addition of anti-CTLA-4 to anti-PD-1 antibody demonstrated superior anti-tumor effects in various malignancies, including melanoma, kidney, and lung cancer [26]. Here, PDCD1 is linked to neoplasm.